NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered PT-141 from Shanxi Qianyecao Biotech QYC? Mail in a sample (US only) and let us test it.

Test my supply
+11 more ↓
72%
Finnrick rating
#8 of 47 PT-141 vendors
3 of 3 classifiable tests passed
natural 100% · customers 4.4★ (2)
methodology · Purity focus
Finnrick analysis · PT-141

Across a broad, recent lab record, Shanxi Qianyecao Biotech QYC shows its strongest purity-focus evidence in GHK-Cu and Tirzepatide, with passing identity, high purity, and acceptable fill. The catalog is uneven: Retatrutide is volatile, while BPC-157 and Cagrilintide carry repeated purity, identity, or fill misses, and missing batch IDs add uncertainty.

methodology →
vendor intelligence report
Vendor Intelligence Report: Shanxi Qianyecao Biotech QYC

Registry filings, WHOIS records and public-channel checks trace QYC from a cancelled PRC entity to a late-2026 verification collapse. The report also follows Revivix COAs, payment-rail changes and the unresolved control behind Amy-QYC.

35 pages7 risk factors assessed12 Nov 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.08
89%
13
2
Tirzepatide
$0.47
81%
22
3
Retatrutide
$1.20
73%
53
4
PT-141selected
$1.80
72%
3
5
Ipamorelin
$1.00
60%
5
6
Tesamorelin
$1.90
57%
12
7
Sermorelin
$2.00
48%
3
8
BPC-157
$1.29
46%
8
9
TB-500
$3.00
41%
4
10
Cagrilintide
$2.40
39%
5
11
NAD+
-
22%
4
12
CJC-1295
$2.00
-
0
13
Epithalon
$0.30
-
0
15
HGH
-
-
0
16
KLOW
-
-
0
17
KPV
-
-
0
18
Semaglutide
$2.00
-
0
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%14 Oct 2025: 62%1 Mar 2026: 68%5 Sep 2026: 72%15 Nov 2026: current 72%62%68%72%Oct 25Nov 26
Showing PT-141 tests only
Shanxi Qianyecao Biotech QYC PT-141 test history
COA-backed lab tests

About Shanxi Qianyecao Biotech QYC test results from Finnrick

Shanxi Qianyecao Biotech QYC is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 11 peptides and 132 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Shanxi Qianyecao Biotech QYC peptides in this dataset are BPC-157 (8 tests), Cagrilintide (5 tests) and GHK-Cu (13 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 132 recent tests. It also includes 1 correction related to this vendor.

Corrections
2026-08-17
Finnrick data entry
The requester submitted the NAD+ sample with a declared potency of 50 mg. The correct potency is 500 mg. The recorded data has been corrected to reflect the accurate potency of 500 mg.
Peptide testing

Ordered PT-141 from Shanxi Qianyecao Biotech QYC? Mail in a sample (US only) and let us test it.

Test my supply